Psivida Corp Com (PSDV) 3.20 $PSDV
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin(R) from Tethadur(TM) Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
GlobeNewswire - Fri Jul 08, 7:29AM CDT
pSivida Corp (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled Release of Avastin from the Tethadur Biodegradable Matrix" at the 2016 Annual Meeting & Exposition of the Controlled Release Society in Seattle, Washington. The poster and presentation, based on research led by pSivida's Dr. Dinesh Nadarassan, will take place on Tuesday, July 19.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
GlobeNewswire - Thu May 05, 3:01PM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, 2016.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris.
OPHT: 54.90 (-0.17), PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
GlobeNewswire - Mon May 02, 6:34AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur(TM) for the treatment of chronic non-infectious uveitis of the posterior of the eye (posterior uveitis).
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Wed Apr 27, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after the market close on Thursday, May 5, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
GlobeNewswire - Thu Mar 24, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at the New York Marriott Marquis on Thursday, March 31, 2016.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
Additional Favorable Six-Month Safety Results for pSivida's Medidur(TM) for Posterior Uveitis
GlobeNewswire - Tue Mar 15, 9:00AM CDT
Small Average Increase in IOP Relative to Control
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
GlobeNewswire - Mon Feb 08, 3:01PM CST
pSivida Corp. (NASDAQ SDV), (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended December 31, 2015.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Mon Feb 01, 11:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after the market close on Monday, February 8, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016.
ALIM: 1.35 (+0.07), PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Closes $17.8 Million Offering
GlobeNewswire - Wed Jan 13, 6:45AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common stock at a public offering price of $4.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 440,000 additional shares of common stock, reflecting gross proceeds to pSivida of $17.8 million. pSivida expects net proceeds from the offering to equal approximately $16.4 million after fees and expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), and Northland Securities acted as the joint book-running managers for the offering.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04), LTS: 2.47 (+0.07)
pSivida Announces Pricing of $16 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 07, 7:20AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $16.0 million. In addition, pSivida has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 440,000 shares of pSivida's common stock.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
BUYINS.NET: NFLX, AGG, PSDV, OSBCP, PRXL, SSNC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Jan 07, 6:32AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Netflix Inc (NASDAQ:NFLX), African Gold Group Inc (NYSE:AGG), pSivida Corp (NASDAQ SDV), Old Second Capital Trust I (NASDAQ:OSBCP), PAREXEL International Corp (NASDAQ RXL), SS&C Technologies Holdings Inc (NASDAQ:SSNC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NFLX: 94.67 (-2.39), SSNC: 29.84 (+0.20), PRXL: 66.16 (-0.04), PSDV: 3.20 (+0.05), AGG: 112.95 (-0.30), OSBCP: 10.22 (unch)
pSivida Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 4:57PM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
Pharma Industry Poised for Fast Start in 2016 as U.S. Food & Drug Administration Receives Requests for Newest Orphan Drug Designations & Rare Disease Treatments
PR Newswire - Tue Dec 29, 7:30AM CST
Biotechnology companies continue to forge ahead with advancing clinical trials and development of next-generation treatments for rare diseases through new orphan drug designations and cutting edge drug delivery products. Today's companies in the spotlight with achievements and recent developments are Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), pSivida Corp. (NASDAQ: PSDV), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Auris Medical Holding AG (NASDAQ: EARS) and Cerus Corporation (NASDAQ: CERS).
CERS: 6.46 (+0.01), EARS: 4.03 (-0.06), ADMS: 15.65 (-0.04), PSDV: 3.20 (+0.05)
pSivida Plans Medidur(TM) EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
GlobeNewswire - Mon Dec 28, 6:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur(TM) for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company's receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Tue Dec 22, 10:51AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that have been attracting the attention of investors.
ARGS: 6.30 (+0.06), PSDV: 3.20 (+0.05), SRNE: 6.44 (-0.27)
pSivida's Medidur(TM) Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
GlobeNewswire - Tue Dec 22, 6:00AM CST
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
BUYINS.NET: PSDV SqueezeTrigger Price is $3.85. There is $3,442,920 That Short Sellers Still Need To Cover.
M2 - Thu Dec 17, 9:59AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring pSivida Corp (NASDAQ SDV) in real time and just received an alert that PSDV is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 882800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.85. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
PSDV: 3.20 (+0.05)
pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
GlobeNewswire - Thu Nov 05, 3:06PM CST
pSivida Corp. (NASDAQ SDV), (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its first fiscal quarter ended September 30, 2015.
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin(R) from Tethadur(TM) Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
GlobeNewswire - Fri Jul 08, 7:29AM CDT
pSivida Corp (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled Release of Avastin from the Tethadur Biodegradable Matrix" at the 2016 Annual Meeting & Exposition of the Controlled Release Society in Seattle, Washington. The poster and presentation, based on research led by pSivida's Dr. Dinesh Nadarassan, will take place on Tuesday, July 19. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
GlobeNewswire - Thu May 05, 3:01PM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, 2016. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris. OPHT: 54.90 (-0.17), PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
GlobeNewswire - Mon May 02, 6:34AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur(TM) for the treatment of chronic non-infectious uveitis of the posterior of the eye (posterior uveitis). PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Wed Apr 27, 8:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after the market close on Thursday, May 5, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
GlobeNewswire - Thu Mar 24, 8:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at the New York Marriott Marquis on Thursday, March 31, 2016. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
Additional Favorable Six-Month Safety Results for pSivida's Medidur(TM) for Posterior Uveitis
GlobeNewswire - Tue Mar 15, 9:00AM CDT
Small Average Increase in IOP Relative to Control
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
GlobeNewswire - Mon Feb 08, 3:01PM CST
pSivida Corp. (NASDAQ
SDV), (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended December 31, 2015. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Mon Feb 01, 11:15AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after the market close on Monday, February 8, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016. ALIM: 1.35 (+0.07), PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
pSivida Closes $17.8 Million Offering
GlobeNewswire - Wed Jan 13, 6:45AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common stock at a public offering price of $4.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 440,000 additional shares of common stock, reflecting gross proceeds to pSivida of $17.8 million. pSivida expects net proceeds from the offering to equal approximately $16.4 million after fees and expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), and Northland Securities acted as the joint book-running managers for the offering. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04), LTS: 2.47 (+0.07)
pSivida Announces Pricing of $16 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 07, 7:20AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $16.0 million. In addition, pSivida has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 440,000 shares of pSivida's common stock. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
BUYINS.NET: NFLX, AGG, PSDV, OSBCP, PRXL, SSNC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Jan 07, 6:32AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Netflix Inc (NASDAQ:NFLX), African Gold Group Inc (NYSE:AGG), pSivida Corp (NASDAQ
SDV), Old Second Capital Trust I (NASDAQ:OSBCP), PAREXEL International Corp (NASDAQ RXL), SS&C Technologies Holdings Inc (NASDAQ:SSNC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: NFLX: 94.67 (-2.39), SSNC: 29.84 (+0.20), PRXL: 66.16 (-0.04), PSDV: 3.20 (+0.05), AGG: 112.95 (-0.30), OSBCP: 10.22 (unch)
pSivida Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 4:57PM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
Pharma Industry Poised for Fast Start in 2016 as U.S. Food & Drug Administration Receives Requests for Newest Orphan Drug Designations & Rare Disease Treatments
PR Newswire - Tue Dec 29, 7:30AM CST
Biotechnology companies continue to forge ahead with advancing clinical trials and development of next-generation treatments for rare diseases through new orphan drug designations and cutting edge drug delivery products. Today's companies in the spotlight with achievements and recent developments are Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), pSivida Corp. (NASDAQ: PSDV), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Auris Medical Holding AG (NASDAQ: EARS) and Cerus Corporation (NASDAQ: CERS).
CERS: 6.46 (+0.01), EARS: 4.03 (-0.06), ADMS: 15.65 (-0.04), PSDV: 3.20 (+0.05)
pSivida Plans Medidur(TM) EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
GlobeNewswire - Mon Dec 28, 6:15AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur(TM) for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company's receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
4 Stocks to Watch Trading Under $500M Market Cap
ACCESSWIRE - Tue Dec 22, 10:51AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com. Today we are focusing on four companies to watch that have been attracting the attention of investors.
ARGS: 6.30 (+0.06), PSDV: 3.20 (+0.05), SRNE: 6.44 (-0.27)
pSivida's Medidur(TM) Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
GlobeNewswire - Tue Dec 22, 6:00AM CST
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy
PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
BUYINS.NET: PSDV SqueezeTrigger Price is $3.85. There is $3,442,920 That Short Sellers Still Need To Cover.
M2 - Thu Dec 17, 9:59AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring pSivida Corp (NASDAQ
SDV) in real time and just received an alert that PSDV is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 882800 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.85. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com . PSDV: 3.20 (+0.05)
pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
GlobeNewswire - Thu Nov 05, 3:06PM CST
pSivida Corp. (NASDAQ
SDV), (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its first fiscal quarter ended September 30, 2015. PSDV: 3.20 (+0.05), PVA: 0.15 (-0.04)
